The US Food and Drug Administration (FDA) has approved the IL-17 inhibiting monoclonal antibody secukinumab (trade name: Cosentyx) to treat severe plaque psoriasis [40]. The gene discussed is IL17A; the disease is psoriasis vulgaris.